Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy.

Short-term oral CBD/CBDA-rich hemp supplementation is safe and well-tolerated in dogs undergoing CHOP chemotherapy for lymphoma.

This prospective, double-blinded, randomized, placebo-controlled clinical trial evaluated the safety, tolerability, and pharmacokinetics of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)-rich hemp oil supplementation in dogs diagnosed with high-grade lymphoma undergoing CHOP chemotherapy. Twenty-five client-owned dogs were enrolled, with 19 completing the study. The intervention group received CBD/CBDA-rich hemp oil capsules, while the control group received a placebo during one cycle of CHOP chemotherapy. Primary outcomes included adverse events, quality of life scores, and doxorubicin area under the curve (AUC) over a 5-week period. Results indicated that CBD/CBDA supplementation did not significantly affect doxorubicin AUC. At week 0, the doxorubicin AUC was 390.8 nM/h (318.6–479.4) for the placebo group and 403.4 nM/h (351.9–462.5) for the CBD/CBDA group. At week 5, the AUC was 572.6 nM/h (448.3–731.2) for the placebo group and 406.8 nM/h (323.2–551.8) for the CBD/CBDA group. No significant differences were observed in hematological and biochemical variables between groups. Quality of life scores ranged from 0 to 35 for the placebo group and 0 to 56 for the CBD/CBDA group, with no significant differences between groups. The study concluded that short-term oral CBD/CBDA-rich hemp supplementation was safe and well-tolerated in dogs undergoing CHOP chemotherapy for lymphoma. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40622742/?utm_source=openai))

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.